Omega-6 DPA and Its 12-lipoxygenase-oxidized Lipids Regulate Platelet Reactivity in a Nongenomic PPARα-dependent Manner

Overview

Journal Blood Adv

Specialty Hematology

Date 2020 Sep 18

PMID 32946570

Citations 16

Authors

Jennifer Yeung

Reheman Adili

Adriana Yamaguchi

Cody J Freedman

Angela Chen

Ryan Shami

Aditi Das

Theodore R Holman

Michael Holinstat

Affiliations

Soon will be listed here.

Abstract

Arterial thrombosis is the underlying cause for a number of cardiovascular-related events. Although dietary supplementation that includes polyunsaturated fatty acids (PUFAs) has been proposed to elicit cardiovascular protection, a mechanism for antithrombotic protection has not been well established. The current study sought to investigate whether an omega-6 essential fatty acid, docosapentaenoic acid (DPAn-6), and its oxidized lipid metabolites (oxylipins) provide direct cardiovascular protection through inhibition of platelet reactivity. Human and mouse blood and isolated platelets were treated with DPAn-6 and its 12-lipoxygenase (12-LOX)-derived oxylipins, 11-hydroxy-docosapentaenoic acid and 14-hydroxy-docosapentaenoic acid, to assess their ability to inhibit platelet activation. Pharmacological and genetic approaches were used to elucidate a role for DPA and its oxylipins in preventing platelet activation. DPAn-6 was found to be significantly increased in platelets following fatty acid supplementation, and it potently inhibited platelet activation through its 12-LOX-derived oxylipins. The inhibitory effects were selectively reversed through inhibition of the nuclear receptor peroxisome proliferator activator receptor-α (PPARα). PPARα binding was confirmed using a PPARα transcription reporter assay, as well as PPARα-/- mice. These approaches confirmed that selectivity of platelet inhibition was due to effects of DPA oxylipins acting through PPARα. Mice administered DPAn-6 or its oxylipins exhibited reduced thrombus formation following vessel injury, which was prevented in PPARα-/- mice. Hence, the current study demonstrates that DPAn-6 and its oxylipins potently and effectively inhibit platelet activation and thrombosis following a vascular injury. Platelet function is regulated, in part, through an oxylipin-induced PPARα-dependent manner, suggesting that targeting PPARα may represent an alternative strategy to treat thrombotic-related diseases.

Citing Articles

Identification of oxylipins and lipid mediators in pulmonary embolism.

Chen F, Peng D, Xia Y, Sun H, Shen H, Xia M Lipids Health Dis. 2024; 23(1):330.

PMID: 39385249 PMC: 11462670. DOI: 10.1186/s12944-024-02315-6.

Platelet dysfunction reversal with cold-stored vs room temperature-stored platelet transfusions.

Kogler V, Miles J, Ozpolat T, Bailey S, Byrne D, Bawcom-Randall M Blood. 2024; 143(20):2073-2088.

PMID: 38427589 PMC: 11143524. DOI: 10.1182/blood.2023022593.

Biofilm-derived oxylipin 10-HOME-mediated immune response in women with breast implants.

Khan I, Minto R, Kelley-Patteson C, Singh K, Timsina L, Suh L J Clin Invest. 2023; 134(3).

PMID: 38032740 PMC: 10849761. DOI: 10.1172/JCI165644.

Antiplatelet strategies: past, present, and future.

Stanger L, Yamaguchi A, Holinstat M J Thromb Haemost. 2023; 21(12):3317-3328.

PMID: 38000851 PMC: 10683860. DOI: 10.1016/j.jtha.2023.09.013.

Investigating the catalytic efficiency of C22-Fatty acids with LOX human isozymes and the platelet response of the C22-oxylipin products.

Tran M, Stanger L, Narendra S, Holinstat M, Holman T Arch Biochem Biophys. 2023; 747:109742.

PMID: 37696384 PMC: 10821779. DOI: 10.1016/j.abb.2023.109742.

References

Unsworth A, Kriek N, Bye A, Naran K, Sage T, Flora G . PPARγ agonists negatively regulate αIIbβ3 integrin outside-in signaling and platelet function through up-regulation of protein kinase A activity. J Thromb Haemost. 2016; 15(2):356-369. PMC: 5396324. DOI: 10.1111/jth.13578. View

Tourdot B, Ahmed I, Holinstat M . The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol. 2014; 4:176. PMC: 3882718. DOI: 10.3389/fphar.2013.00176. View

Han J, Kim B, Won J, Shin Y, Choi S, Hwang I . Interaction between platelets and endothelial progenitor cells via LPA-Edg-2 axis is augmented by PPAR-δ activation. J Mol Cell Cardiol. 2016; 97:266-77. DOI: 10.1016/j.yjmcc.2016.06.002. View

Li D, Chen K, Sinha N, Zhang X, Wang Y, Sinha A . The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005; 65(4):907-12. DOI: 10.1016/j.cardiores.2004.11.027. View

Ikei K, Yeung J, Apopa P, Ceja J, Vesci J, Holman T . Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation. J Lipid Res. 2012; 53(12):2546-59. PMC: 3494251. DOI: 10.1194/jlr.M026385. View

Ali F, Hall M, Desvergne B, Warner T, Mitchell J . PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. Arterioscler Thromb Vasc Biol. 2009; 29(11):1871-3. DOI: 10.1161/ATVBAHA.109.193367. View

Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S . Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019; 73(22):2791-2802. DOI: 10.1016/j.jacc.2019.02.032. View

Adili R, Tourdot B, Mast K, Yeung J, Freedman J, Green A . First Selective 12-LOX Inhibitor, ML355, Impairs Thrombus Formation and Vessel Occlusion In Vivo With Minimal Effects on Hemostasis. Arterioscler Thromb Vasc Biol. 2017; 37(10):1828-1839. PMC: 5620123. DOI: 10.1161/ATVBAHA.117.309868. View

Cherpokova D, Jouvene C, Libreros S, DeRoo E, Chu L, De La Rosa X . Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood. 2019; 134(17):1458-1468. PMC: 6839959. DOI: 10.1182/blood.2018886317. View

10.

Bhatt D, Steg P, Miller M, Brinton E, Jacobson T, Ketchum S . Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2018; 380(1):11-22. DOI: 10.1056/NEJMoa1812792. View

11.

Li H, Gomes P, Chen J . RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A. 1997; 94(16):8479-84. PMC: 22964. DOI: 10.1073/pnas.94.16.8479. View

12.

Munoz-Gutierrez C, Sepulveda C, Caballero J, Palomo I, Fuentes E . Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci. 2017; 186:59-65. DOI: 10.1016/j.lfs.2017.07.031. View

13.

Sprecher H, Careaga M . Metabolism of (n-6) and (n-3) polyunsaturated fatty acids by human platelets. Prostaglandins Leukot Med. 1986; 23(2-3):129-34. DOI: 10.1016/0262-1746(86)90175-7. View

14.

Kutzner L, Goloshchapova K, Heydeck D, Stehling S, Kuhn H, Schebb N . Mammalian ALOX15 orthologs exhibit pronounced dual positional specificity with docosahexaenoic acid. Biochim Biophys Acta Mol Cell Biol Lipids. 2017; 1862(7):666-675. DOI: 10.1016/j.bbalip.2017.04.001. View

15.

Phipps R, Blumberg N . Statin islands and PPAR ligands in platelets. Arterioscler Thromb Vasc Biol. 2009; 29(5):620-1. PMC: 2745197. DOI: 10.1161/ATVBAHA.109.184648. View

16.

Bhatt D, Steg P, Brinton E, Jacobson T, Miller M, Tardif J . Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017; 40(3):138-148. PMC: 5396348. DOI: 10.1002/clc.22692. View

17.

Yeung J, Li W, Holinstat M . Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacol Rev. 2018; 70(3):526-548. PMC: 6013590. DOI: 10.1124/pr.117.014530. View

18.

Yeung J, Tourdot B, Adili R, Green A, Freedman C, Fernandez-Perez P . 12(S)-HETrE, a 12-Lipoxygenase Oxylipin of Dihomo-γ-Linolenic Acid, Inhibits Thrombosis via Gαs Signaling in Platelets. Arterioscler Thromb Vasc Biol. 2016; 36(10):2068-77. PMC: 5488693. DOI: 10.1161/ATVBAHA.116.308050. View

19.

Kliewer S, Sundseth S, Jones S, Brown P, Wisely G, Koble C . Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997; 94(9):4318-23. PMC: 20720. DOI: 10.1073/pnas.94.9.4318. View

20.

Browning L, Walker C, Mander A, West A, Madden J, Gambell J . Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr. 2012; 96(4):748-58. PMC: 3441107. DOI: 10.3945/ajcn.112.041343. View